CND Life Sciences, an innovative medical diagnostics company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, has been awarded a $2.4 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH).
Will Advance the Company’s Technology Designed to Aid the Diagnosis of Parkinson’s Disease and Other Neurological Disorders
Strong market adoption of Syn-One Test™ to help clinicians diagnose Parkinson’s Disease and other neurological disorders
Grant Supports the Continued Validation and Enhancement of the Syn-One Test™ To Help Physicians Diagnose Parkinson’s Disease and Other Serious Disorders
CND will use its novel cutaneous neurodiagnostics platform to detect and measure changes in TDP-43 in patients treated with edaravone
Company launches the Syn-One Test™ as the first commercially available skin-based test to help physicians confirm diagnosis of Parkinson’s disease and other neurodegenerative disorders